Protein hydrolysate co-ingestion does not modulate 24 h glycemic control in long-standing type 2 diabetes patients.
OBJECTIVE
Evaluate the efficacy of protein hydrolysate co-ingestion as a dietary strategy to improve blood glucose homeostasis under free-living conditions in long-standing type 2 diabetes patients.


METHODS
A total of 13 type 2 diabetes patients were enrolled in a randomized, double-blind cross-over design and studied on two occasions for 40 h under strict dietary standardization but otherwise normal, free-living conditions. In one trial, subjects ingested a protein hydrolysate (0.4 g kg(-1) bw casein hydrolysate, PRO) with every main meal. In the other trial, a placebo was ingested (PLA). Blood glucose concentrations were assessed by continuous glucose monitoring.


RESULTS
Average 24 h glucose concentrations were similar between the PLA and the PRO trials (8.9 +/- 0.8 vs 9.2 +/- 0.7 mmol l(-1), respectively). Hyperglycemia (glucose concentrations >10 mmol l(-1)) was experienced 34 +/- 9% of the time (8 +/- 2 h per 24 h) in the PLA trial. Protein hydrolysate co-ingestion with each main meal (PRO) did not reduce the prevalence of hyperglycemia (39 +/- 10%, 9 +/- 2 h per 24 h; P=0.2).


CONCLUSIONS
Co-ingestion of a protein hydrolysate with each main meal does not improve glucose homeostasis over a 24 h period in long-standing type 2 diabetes patients.
Manders
R J F
RJ
Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University, Maastricht, The Netherlands. R.Manders@HB.unimaas.nl
Praet
S F E
SF
Vikström
M H
MH
Saris
W H M
WH
van Loon
L J C
LJ
D001786:Blood Glucose / Q000378:metabolism*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007930:Leucine / Q000627:therapeutic use*; D008875:Middle Aged; D011492:Protein Hydrolysates / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011492:Protein Hydrolysates; D007930:Leucine